Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-T-DART: Daratumumab Post-HCT in High Risk T-ALL and T-LLy
NCT04972942Phase 1Recruiting
- Sponsor
- New York Medical College
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by New York Medical College. Primary endpoint: Dose Limiting Toxicity at 60 days. Started May 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04972942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972942.